RE: Funding , a DIRTY word ?19 Jun 2020 15:30
Of course the CEO will be watching the financial situation.
It's generally partnering rather than funding in Biotech as they tend to prove up the concept then either get bought outright or partner with a bigger company to develop it (hence the RNS mentioning money allocated for: "Strengthened balance sheet for potential partnering discussions with regards to the COVID-19, future pandemic preparedness, and the COPD opportunity").
There's also a reasonable chance there will be no P3 in COVID if this trial is well recruited and works. With the numbers they're talking about in the trial (100-600) that could easily be enough. In the current situation, I'd actually probably be more surprised if they did phase III trials, than if they didn't, and don't see why it wouldn't be pushed into production, if the data is good. Interferon beta is a known substance and from all the various trials they've done they'd have more than enough safety data.